The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -2.99 — distress zone — historically elevated failure riskWatch
- Earnings-manipulation signal · Beneish M -2.56 — no flag raisedOK
- Earnings quality 100/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2025, as Xeris Biopharma Holdings, Inc. reports it. History and quarterly detail are in the app.
- Product revenue, net$283.0M
- Recorlev$139.3M
- Gvoke$94.1M
- Keveyis$47.6M
- Royalty, contract and other revenue$8.8M
Leadership changes
From Xeris Biopharma Holdings, Inc.'s own filings, the day they're filed.
- Ken Johnson · President · departureeff. 2025-04-01
- Ricki Fairley · director · departureeff. 2025-03-28
- James Brady · director · departureeff. 2025-03-28
Latest filings
- 8-K · Company announcement2026-08-06
- 10-Q · Quarterly report2026-08-06
- 8-K · Company announcement2026-07-17
- 8-K · Company announcement2026-06-30
- 8-K · Company announcement2026-06-11
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Xeris Biopharma Holdings, Inc., every answer cited to the official filings🔒
- The Intelligence Brief — added when Xeris Biopharma Holdings, Inc.'s brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.